NCT00883480 2022-06-13
SLAT
Spanish Lung Cancer Group
Phase NA Completed
Clinical Trials
11 trialsNCT01636908 2021-04-15
ICK
Amsterdam UMC, location VUmc
Phase NA Completed
NCT01190241 2020-11-20
TSAP
Amsterdam UMC, location VUmc
Phase NA Terminated
NCT04007835 2019-07-05
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Guangdong Association of Clinical Trials
Phase NA Unknown
NCT00503841 2019-04-30
Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer
Barbara Ann Karmanos Cancer Institute
Phase NA Terminated
NCT00125372 2019-01-08
Study of Tarceva and Targretin in Stage I-II Lung Cancer
Dartmouth-Hitchcock Medical Center
Phase NA Completed
NCT02450591 2018-05-21
Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations
Memorial Sloan Kettering Cancer Center
Phase NA Completed
NCT02013089 2016-08-30
GITIC
Sun Yat-sen University
Phase NA Unknown
NCT00144976 2015-03-27
Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma
Institut Claudius Regaud
Phase NA Completed
NCT01776684 2013-01-28
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
Samsung Medical Center
Phase NA Unknown
NCT00903292 2009-05-18
Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma
National Cheng-Kung University Hospital
Phase NA Unknown